These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2273211)

  • 1. Resistance to a long-acting somatostatin analog (SMS 201-995) reversed by surgery in acromegaly.
    Attanasio R; Chiodini PG; Liuzzi A; Orlandi P; De Palo C; Dallabonzana D; Lodrini A; Cozzi R
    J Endocrinol Invest; 1990 Sep; 13(8):683-7. PubMed ID: 2273211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery.
    Lucas-Morante T; García-Uría J; Estrada J; Saucedo G; Cabello A; Alcañiz J; Barceló B
    J Neurosurg; 1994 Jul; 81(1):10-4. PubMed ID: 8207509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
    Shi YF; Harris AG; Zhu XF; Deng JY
    Clin Endocrinol (Oxf); 1990 Jun; 32(6):695-705. PubMed ID: 2200620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desensitization to somatostatin analogue (Octreotide) observed in a patient with acromegaly.
    Haraguchi K; Ohtaka M; Takazawa K; Endo T; Onaya T
    Endocr J; 1995 Apr; 42(2):295-300. PubMed ID: 7627275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
    Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
    J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a long-acting somatostatin analogue (SMS 201-995) on a growth hormone and thyroid stimulating hormone-producing pituitary tumor.
    Hirasawa R; Hashimoto K; Makino S; Suemaru S; Takao T; Ota Z; Hoshida Y; Yoshino T; Akagi T
    Acta Med Okayama; 1991 Apr; 45(2):107-15. PubMed ID: 1867112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
    Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
    Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone rebound after cessation of sms 201-995 treatment in acromegaly.
    Charest L; Comtois R; Beauregard H; Serri O
    Can J Neurol Sci; 1989 Nov; 16(4):442-5. PubMed ID: 2804808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GH-releasing hormone (GHRH) test in acromegaly before and after adenomectomy.
    Giusti M; Lomeo A; Monachesi M; Mazzocchi G; Attanasio R; Sessarego P; Mignone D; Del Monte P; Giordano G
    J Endocrinol Invest; 1987 Apr; 10(2):143-51. PubMed ID: 3108356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor.
    Melmed S; Ziel FH; Braunstein GD; Downs T; Frohman LA
    J Clin Endocrinol Metab; 1988 Aug; 67(2):395-9. PubMed ID: 2899089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
    Lamberts SW; Uitterlinden P; del Pozo E
    J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate.
    Barkan AL; Lloyd RV; Chandler WF; Hatfield MK; Gebarski SS; Kelch RP; Beitins IZ
    J Clin Endocrinol Metab; 1988 Nov; 67(5):1040-8. PubMed ID: 2903168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical McCune-Albright syndrome associated with growth hormone-prolactin pituitary adenoma: natural history, long-term follow-up, and SMS 201-995--bromocriptine combined treatment results.
    Cremonini N; Graziano E; Chiarini V; Sforza A; Zampa GA
    J Clin Endocrinol Metab; 1992 Oct; 75(4):1166-9. PubMed ID: 1400888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
    Yin J; Su CB; Xu ZQ; Yang Y; Ma WB; Tao W; Yang Z; Xia XW
    Chin Med Sci J; 2005 Mar; 20(1):23-6. PubMed ID: 15844307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin analog treatment of acromegaly: new aspects.
    Lamberts SW; del Pozo E
    Horm Res; 1988; 29(2-3):115-7. PubMed ID: 2900190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acromegaly from ectopic growth hormone-releasing hormone secretion by a malignant carcinoid tumor. Successful treatment with long-acting somatostatin analogue SMS 201-995.
    Barkan AL; Shenker Y; Grekin RJ; Vale WW
    Cancer; 1988 Jan; 61(2):221-6. PubMed ID: 2891432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.